Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for depression in alcohol-dependent adults
ACTRN12610000390088Phase 3Not yet recruiting
- Sponsor
- University of Otago
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and alcohol dependence (2 cohorts), sponsored by University of Otago. Primary endpoints: Depression remission and Reduction in alcohol consumption. Planned start Sep 2010; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)alcohol dependence
Beyond the preview
Go deeper on ACTRN12610000390088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000390088.